{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:52:15Z","timestamp":1791229935957,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1245\/s10434-022-11838-0","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T16:02:45Z","timestamp":1653148965000},"page":"5722-5729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Manifestations and Surgical Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Beyond the NCCN Guidelines"],"prefix":"10.1245","volume":"29","author":[{"given":"Heather A.","family":"Lillemoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto N.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"11838_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamasurg.2017.4026","volume":"152","author":"AN Leberfinger","year":"2017","unstructured":"Leberfinger AN, Behar BJ, Williams NC, et al. Breast implant-associated anaplastic large cell lymphoma: a systematic review. JAMA Surg. 2017;152:1161\u20138.","journal-title":"JAMA Surg."},{"key":"11838_CR2","doi-asserted-by":"publisher","first-page":"785887","DOI":"10.3389\/fonc.2021.785887","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang Q, Tan Y, et al. Current progress in breast implant-associated anaplastic large cell lymphoma. Front Oncol. 2021;11:785887.","journal-title":"Front Oncol."},{"key":"11838_CR3","unstructured":"U.S. Food and Drug Administration. Allergen Recalls Natrelle Biocell Textured Breast Implants Due to Risk of BIA-ALCL Cancer. Retrieved 24 October 2021 at https:\/\/www.fda.gov\/medical-devices\/safety-communications\/fda-requests-allergan-voluntarily-recall-natrelle-biocell-textured-breast-implants-and-tissue."},{"key":"11838_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.bjps.2019.11.064","volume":"73","author":"PG Cordeiro","year":"2020","unstructured":"Cordeiro PG, Ghione P, Ni A, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. J Plast Reconstr Aesthet Surg. 2020;73:841\u20136.","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"11838_CR5","doi-asserted-by":"publisher","first-page":"101963","DOI":"10.1016\/j.ctrv.2020.101963","volume":"84","author":"A Marra","year":"2020","unstructured":"Marra A, Viale G, Pileri SA, et al. Breast implant-associated anaplastic large cell lymphoma: a comprehensive review. Cancer Treat Rev. 2020;84:101963.","journal-title":"Cancer Treat Rev"},{"key":"11838_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/asj\/sjw259","volume":"37","author":"MW Clemens","year":"2017","unstructured":"Clemens MW, Horwitz SM. NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J. 2017;37:285\u20139.","journal-title":"Aesthet Surg J"},{"key":"11838_CR7","unstructured":"NCCN. National Comprehensive Cancer Network. Retrieved 24 October 2021 at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf."},{"issue":"2","key":"11838_CR8","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1097\/SLA.0000000000004035","volume":"275","author":"SE Tevis","year":"2022","unstructured":"Tevis SE, Hunt KK, Miranda RN, et al. Breast implant-associated anaplastic large cell lymphoma: a prospective series of 52 patients. Ann Surg. 2022;275(1):e245\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000004035.","journal-title":"Ann Surg"},{"key":"11838_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2015.63.3412","volume":"34","author":"MW Clemens","year":"2016","unstructured":"Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34:160\u20138.","journal-title":"J Clin Oncol"},{"issue":"3S","key":"11838_CR10","doi-asserted-by":"publisher","first-page":"65s","DOI":"10.1097\/PRS.0000000000005571","volume":"143","author":"CM McCarthy","year":"2019","unstructured":"McCarthy CM, Loyo-Berr\u00edos N, Qureshi AA, et al. Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): initial report of findings 2012\u20132018 (a review of breast implant-associated anaplastic large cell lymphoma). Plast Reconstr Surg. 2019;143(3S):65s\u201373s.","journal-title":"Plast Reconstr Surg"},{"key":"11838_CR11","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190\u20136.","journal-title":"J Clin Oncol"},{"key":"11838_CR12","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812\u201321.","journal-title":"N Engl J Med"},{"issue":"3S","key":"11838_CR13","doi-asserted-by":"publisher","first-page":"51S","DOI":"10.1097\/PRS.0000000000005569","volume":"143","author":"GA Lamaris","year":"2019","unstructured":"Lamaris GA, Butler CE, Deva AK, et al. Breast reconstruction following breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2019;143(3S):51S\u201358S. https:\/\/doi.org\/10.1097\/PRS.0000000000005569.","journal-title":"Plast Reconstr Surg"},{"key":"11838_CR14","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/j.clml.2020.12.005","volume":"21","author":"S Alotaibi","year":"2021","unstructured":"Alotaibi S, Hamadani M, Al-Mansour M, Aljurf M. Breast implant-associated anaplastic large cell lymphoma. Clin Lymphoma Myeloma Leukemia. 2021;21:e272\u20136.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"11838_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/PAS.0000000000000985","volume":"42","author":"MC Ferrufino-Schmidt","year":"2018","unstructured":"Ferrufino-Schmidt MC, Medeiros LJ, Liu H, et al. Clinicopathologic features and prognostic impact of lymph node involvement in patients with breast implant-associated anaplastic large cell lymphoma. Am J Surg Pathol. 2018;42:293\u2013305.","journal-title":"Am J Surg Pathol"},{"key":"11838_CR16","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41379-021-00842-6","volume":"34","author":"MG Evans","year":"2021","unstructured":"Evans MG, Medeiros LJ, Marques-Piubelli ML, et al. Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. Mod Pathol. 2021;34:2148\u201353.","journal-title":"Mod Pathol"},{"key":"11838_CR17","unstructured":"ASAPS and ASPS BIA-ALCL Advisory Update. Retrieved 14 February 2022 at https:\/\/www.surgery.org\/sites\/default\/files\/BIA-7-31-18.pdf."},{"key":"11838_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229\u201340.","journal-title":"Lancet"},{"issue":"3S","key":"11838_CR19","doi-asserted-by":"publisher","first-page":"41S","DOI":"10.1097\/PRS.0000000000005568","volume":"143","author":"MS Collins","year":"2019","unstructured":"Collins MS, Miranda RN, Medeiros LJ, et al. Characteristics and treatment of advanced breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2019;143(3S):41S\u201350S. https:\/\/doi.org\/10.1097\/PRS.0000000000005568.","journal-title":"Plast Reconstr Surg"},{"key":"11838_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijwd.2017.05.005","volume":"3","author":"N Shahriari","year":"2017","unstructured":"Shahriari N, Ferenczi K, Heald PW. Breast implant-associated anaplastic large cell lymphoma: a review and assessment of cutaneous manifestations. Int J Womens Dermatol. 2017;3:140\u20134.","journal-title":"Int J Womens Dermatol"},{"key":"11838_CR21","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1097\/PRS.0b013e3182172418","volume":"127","author":"B Kim","year":"2011","unstructured":"Kim B, Roth C, Chung KC, et al. Anaplastic large cell lymphoma and breast implants: a systematic review. Plast Reconstr Surg. 2011;127:2141\u201350.","journal-title":"Plast Reconstr Surg"},{"key":"11838_CR22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/cup.12697","volume":"43","author":"R Alcal\u00e1","year":"2016","unstructured":"Alcal\u00e1 R, Llombart B, Lavernia J, Traves V, Guill\u00e9n C, Sanmart\u00edn O. Skin involvement as the first manifestation of breast implant-associated anaplastic large cell lymphoma. J Cutan Pathol. 2016;43:602\u20138.","journal-title":"J Cutan Pathol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11838-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11838-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11838-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T17:10:14Z","timestamp":1659805814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11838-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["11838"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11838-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"22 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kelly Hunt is on the medical advisory board of Armada Health and AstraZeneca and has institutional research funding from Cairn Surgical, Eli Lilly & Co., and Lumicell. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}